Clinical trials: psoriasis
Generalized Pustular Psoriasis
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis
The main objectives of this study are to evaluate the efficacy, safety and tolerability of imsidolimab in adults with active GPP.
- Trial name
- GPP (NCT03619902)
- Testing
- Imsidolimab
- Where
- 13 sites in United States, Poland and 2 more
- Volunteers
- 8 people
- Sponsor
- Vanda Pharmaceuticals
Psoriasis
The Effect of NB-UVB on Interleukin-36 Levels in Psoriasis
Psoriasis is an immune-mediated skin disease that affects 1-2 % of the population. Several cytokines have been found to be involved in the complex pathogenesis of this disease.
- Trial name
- NCT03526705
- Testing
- NB-UVB
- Volunteers
- 25 people
- Sponsor
- Cairo University
Moderate to Severe Plaque Psoriasis
Open Label Continuation Study in Moderate to Severe Psoriasis
The purpose of this study is to evaluate long term safety, efficacy and tolerability of ABT-874 in adults with moderate to severe psoriasis.
- Trial name
- NCT00626002
- Testing
- ABT-874
- Where
- 152 sites in United States, Austria and 12 more
- Volunteers
- 2,301 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
The Impact of COVID19 on Psoriasis Patients
Impact of COVID 19 on Psoriasis Patients
The main objective of this work is to investigate the effect of COVID-19 pandemic on psoriasis patients. This work is designed as a cross-sectional survey based on a questionnaire directed to Egyptian psoriasis patients.
- Trial name
- NCT05381402
- Testing
- Questionnaire
- Volunteers
- 230 people
- Sponsor
- Cairo University
Chronic Inflammatory Disease, Angioedema
Deployment o the Multidisciplinary Prospective Cohort Imminent
Immune-mediated inflammatory diseases (IMIDs) most often affect young patients and have high impact on morbidity and mortality with a significant alteration in the quality of life of patients with professional, social and…
- Conditions
- Chronic Inflammatory Disease, Angioedema, Severe Asthma, Lupus
- Trial name
- IMMINeNT (NCT04334031)
- Testing
- Biobanking with genetic analysis, SF-12 questionnaire
- Where
- France
- Volunteers
- 2,200 people
- Sponsor
- University Hospital, Lille
Rheumatic Diseases, Inflammatory Arthritis
Personalized Outreach for Equitable Treatment in Rheumatology
The primary goal of this study is to determine whether providing patient honoraria and/or outreach services can improve the attendance rate of appointments at an inner city rheumatology clinic in Vancouver, British Columbia.
- Conditions
- Rheumatic Diseases, Inflammatory Arthritis, Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
- Trial name
- POET-Rheum (NCT07022756)
- Testing
- Honoraria, Outreach
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University of British Columbia
Psoriasis Vulgaris
Comparison of Refined and Crude Indigo Naturalis Ointment in Treating Psoriasis
To compare the efficacy and safety of refined indigo naturalis ointment with that of crude ointment in treating psoriasis.
- Trial name
- NCT01022502
- Testing
- refined indigo naturalis ointment, crude indigo naturalis ointment
- Where
- Taiwan
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Yin-ku Lin
Venous Thromboses, Venous Thromboembolism
The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study
Blood clots occurring in the legs and in the lungs are relatively common; they occur in around 3 in a 1000 people per year. They can cause disability and are also potentially life threatening.
- Conditions
- Venous Thromboses, Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- NCT03835780
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 266,890 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Arthritis, Psoriatic
Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE)
This will be a Canadian observational study utilizing a prospective cohort design. Patients with active psoriatic arthritis (PsA) for whom the treating physician has decided, prior to and independently of enrollment in the study…
- Trial name
- APPRAISE (NCT03608657)
- Testing
- Apremilast
- Where
- 19 sites in Canada
- Volunteers
- 102 people
- Sponsor
- Amgen
Dermatitis, Nevus
Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles
This study will evaluate whether digital photography is a reliable tool for diagnosing hand rashes, psoriasis and unusual moles.
- Conditions
- Dermatitis, Nevus, Psoriasis
- Trial name
- NCT00005781
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- National Cancer Institute (NCI)
Psoriasis
A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g
This is an open-label, multicenter study designed to evaluate the efficacy and safety of efalizumab administered at weekly SC (subcutaneous) doses of 1.0 mg/kg followed by efalizumab taper in subjects with plaque psoriasis who…
- Trial name
- NCT00109252
- Testing
- Raptiva (efalizumab)
- Sponsor
- Genentech, Inc.
Psoriatic Arthritis
A Study to Assess the Change in Disease State in Adult Participants Being Treated With Oral Upadacitinib Tablets in Participants With Oligo- or Poly-artIcular Psoriatic Arthritis
Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis.
- Trial name
- UPJOINT (NCT04758117)
- Where
- 93 sites in Canada, Germany
- Volunteers
- 394 people
- Sponsor
- AbbVie
Psoriasis
An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to demonstrate the superiority of CNTO 1959 (guselkumab) to placebo in the treatment of participants with moderate to severe plaque-type psoriasis (A common genetically determined, chronic…
- Trial name
- NCT02325219
- Testing
- CNTO 1959 50 mg, CTNO 1959 100 mg
- Where
- 27 sites in Japan
- Volunteers
- 192 people
- Sponsor
- Janssen Pharmaceutical K.K.
Groin Infection, Neurodermatitis
The Novel Electrolyzed Water Spray Treatment Mild Senile Groin Eczema, Neurodermatitis and Psoriasis
The purpose of this study is to test whether spraying the itching of inflammation skin and groin patients by use of the novel electrolyzed water spray will produce improvement in the condition of itching.
- Conditions
- Groin Infection, Neurodermatitis, Psoriasis, Eczema
- Trial name
- NCT05770271
- Testing
- The novel electrolyzed water spray
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Dove Medical Press Ltd
Plaque Psoriasis
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
This is a parallel group, double blind, vehicle-controlled study in which roflumilast (ARQ-151) cream 0.3%, roflumilast cream 0.15%, or vehicle cream is applied once daily (QD) for 84 days to subjects with chronic plaque…
- Trial name
- ARQ-151-201 (NCT03638258)
- Testing
- Roflumilast Cream 0.3%, Roflumilast Cream 0.15%, Vehicle Cream
- Where
- 30 sites in United States, Canada
- Volunteers
- 331 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Psoriasis Vulgaris
Psoriatic Immune Response to Tildrakizumab
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.
- Trial name
- NCT05390515
- Testing
- Tildrakizumab Prefilled Syringe
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Psoriasis
AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects
Investigational drug AMG 714 will be given to 66 subjects with moderate to severe psoriasis to study safety, pharmacokinetics, and efficacy.
- Trial name
- NCT00443326
- Testing
- AMG 714
- Volunteers
- 22 people
- Sponsor
- Amgen
Chronic Plaque Psoriasis
Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis
This study will assess the safety and efficacy of secukinumab compared to placebo and etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis.
- Trial name
- FIXTURE (NCT01358578)
- Testing
- secukinumab (AIN457), etanercept
- Where
- 152 sites in United States, Argentina and 21 more
- Volunteers
- 1,306 people
- Sponsor
- Novartis Pharmaceuticals
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis
This was an observational, prospective primary data collection study. The duration of observation was 2 years after study enrolment date.
- Conditions
- Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
- Trial name
- PROMPT (NCT05155098)
- Testing
- secukinumab
- Where
- 10 sites in Thailand
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis, Atopic Dermatitis
Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis
This is a randomized, placebo-controlled Phase 2 trial consisting of up to 300 subjects with either psoriasis or atopic dermatitis. In this trial BMX-010 will be topically applied twice daily for up to 28 days.
- Trial name
- NCT03381625
- Testing
- BMX-010
- Where
- 10 sites in United States
- Volunteers
- 139 people
- Sponsor
- BioMimetix JV, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.